The Novahox vaccine is 89% effective against corona – global markets

The American biotechnology company Novax (symbol: NVAX) reported that it too has been able to develop an effective vaccine against corona. According to the report, her vaccine is 89.3% effective, according to an experiment among 15,000 people, with six cases of corona patients being detected among those vaccinated, while 56 cases were found in the placebo vaccine.

According to the announcement, the vaccine is 95.6% effective against the original corona virus and 85.6% against the British mutation. The company further said that similar to Pfizer and Modernana vaccines, the vaccine is less effective against the mutation found in South Africa (50% -60% efficacy) and that it has also started developing a vaccine that can deal with this mutation. According to its estimates, it will begin clinical trials during the second quarter of 2021.

In response to the company’s announcement, the stock is now soaring pre-US by 52%.

Unlike the Pfizer vaccine which must be kept in minus 70 degrees, and like the Modern company vaccine, the new Novax vaccine can be stored relatively easily, at room temperature and in regular refrigerators. The advantage of the new vaccine is that it can be stored for a longer period than the modern vaccine, which is stored for up to 30 days only.

Modern’s vaccine, it will be recalled, is also weaker against the South African virus – Expansion here. At the same time, Eli Lilly reported that in her experiment, antibodies created from Pfizer and Modernena vaccines were found to be less effective against the South African mutation, which shows much higher resistance than the initial version of the corona virus.